Urgent Notice for Cardlytics, Inc. Investors
The Law Offices of Howard G. Smith is reaching out to encourage all investors who purchased shares of Cardlytics, Inc. (CDLX) to consider participating in a class action lawsuit. This lawsuit addresses potential securities fraud that may have affected your investments.
Details of the Class Action
Cardlytics investors have until a specified date to file a lead plaintiff motion. This deadline underscores the importance of acting swiftly for those who may have experienced investment losses.
Understanding the Situation
Investors may find themselves uncertain, especially following recent corporate disclosures. On May 8, it was revealed that Cardlytics saw only an 8% revenue increase for the first quarter compared to the previous year. This was disappointing in light of a 12% rise in billings, primarily due to increased consumer incentives that spiked by 20.2%.
Significant Stock Price Drop
After the announcement, Cardlytics' share price took a substantial hit, dropping by $5.33, or 36.5%, to close at $9.27 on May 9. This marked a troubling trend for investors. Later, on August 7, the company’s second quarter results reflected a 9% decline in revenue alongside a noted drop in adjusted contribution margins. Consequently, the stock price again plunged, closing at $2.96 on August 8.
Core Allegations of the Lawsuit
The class action lawsuit claims that Cardlytics and its executives made several misleading statements throughout the specified period. They allegedly failed to disclose key adverse facts about the company’s operations, business health, and growth prospects. The failure to accurately communicate these significant factors led to investor losses.
Past Performance and Concerns
Despite increases in consumer engagement, which typically would suggest a prosperous trajectory for Cardlytics, the reality revealed a different story. Investors were left unaware of the growing issue of mounting consumer incentives, which suggested that billing expectations weren't being met and revenue would likely stagnate or fall.
Ensuring Investor Rights
If you have purchased Cardlytics stock, it's advisable to understand your rights and potential recovery options. The Law Offices of Howard G. Smith is available to help you navigate this complex situation. Contact them via telephone or email to discuss your participation in this lawsuit.
Contact Information for Legal Assistance
To inquire about participating in the securities fraud lawsuit or to learn more about your legal options, reach out to the Law Offices of Howard G. Smith directly. This could be an important step in exercising your legal rights as an investor.
Law Offices of Howard G. Smith - Key Contacts
Located at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, you can contact them by calling (215) 638-4847 or via email at howardsmith@howardsmithlaw.com.
Frequently Asked Questions
What is the lawsuit about?
The lawsuit addresses potential securities fraud allegations against Cardlytics for making misleading statements about its business health and prospects.
Who can participate in the class action?
Anyone who purchased Cardlytics securities during the stated class period may be eligible to participate.
When is the deadline to file a motion?
The specific deadline to file a lead plaintiff motion has been established, and timely action is critical for interested investors.
How can I learn more about my rights?
Investors are encouraged to reach out directly to legal counsel for detailed information about their rights and options for participation.
What happened to the stock price of Cardlytics?
Following the company's financial disclosures, Cardlytics' stock has experienced significant declines, reflecting investor concern and loss.
